Evidence map›Paper›PMID 28028768›Full record

Trial reportPharmaceutical research2017

Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.

Kathleen Panter Faber, Hsin-Fang Wu, Marc R Yago, Xiaohui Xu, Pathanjali Kadiyala, Lynda A Frassetto, Leslie Z Benet

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The effect of pH stability and aqueous solubility on the oral bioavailability of a novel antileishmanial agent.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathleen Panter FaberDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, 533 Parnassus Ave., Room U-68, San Francisco, CA, 94143-0912, USA.
Hsin-Fang WuDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, 533 Parnassus Ave., Room U-68, San Francisco, CA, 94143-0912, USA.
Marc R YagoDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, 533 Parnassus Ave., Room U-68, San Francisco, CA, 94143-0912, USA.
Xiaohui XuBioanalytical Sciences, Bristol-Myers Squibb, Princeton, New Jersey, USA.
Pathanjali KadiyalaBioanalytical Sciences, Bristol-Myers Squibb, Princeton, New Jersey, USA.
Lynda A FrassettoDepartment of Medicine University of California San Francisco, San Francisco, California, USA.
Leslie Z BenetDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, 533 Parnassus Ave., Room U-68, San Francisco, CA, 94143-0912, USA. leslie.benet@ucsf.edu.
University of California, San Francisco · USBioanalytical Systems (United States) · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
NCATS NIH HHS UL1 TR000004
6 · The paper itself

Abstract

purposeClinically relevant pharmacokinetic interactions exist between gastric acid-reducing agents and certain weakly basic drugs that rely on acidic environments for optimal oral absorption. In this study, we examine whether the administration of betaine hydrochloride under fed conditions can enhance the absorption of atazanavir, an HIV-1 protease inhibitor, during pharmacologically-induced hypochlorhydria.

methodsIn this randomized, single-dose, 3 period, crossover study healthy volunteers received ritonavir-boosted atazanavir (atazanavir/ritonavir 300/100 mg) alone, following pretreatment with the proton pump inhibitor rabeprazole (20 mg twice daily), and with 1500 mg of betaine HCl after rabeprazole pretreatment. Atazanavir was administered with a light meal and gastric pH was monitored using the Heidelberg Capsule.

resultsPretreatment with rabeprazole resulted in significant reductions in atazanavir C

conclusionsThe co-administration of rabeprazole with atazanavir resulted in significant decreases in atazanavir exposure. The addition of betaine HCl did not sufficiently mitigate the loss of ATV exposure observed during RAB-induced hypochlorhydria. Meal effects lead to a marked difference in the outcome of betaine HCl on atazanavir exposure than we previously reported for dasatanib under fasting conditions.

Indexed as

Food-Drug InteractionsAbsorption, PhysiologicalAchlorhydriaAdministration, OralAdultAtazanavir SulfateBetaineCross-Over StudiesDrug InteractionsFemaleHIV Protease InhibitorsHumansMaleMiddle AgedProton Pump InhibitorsRabeprazoleAtazanavir SulfateBetaineHIV Protease InhibitorsProton Pump InhibitorsRabeprazoleRitonavirabsorptionatazanavirfood effectsPPIsweakly basic drugs

Identifiers

PMID28028768
PMCPMC7179955
OpenAlexW2564306451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.